Drug Interactions between Acid Controller Maximum Strength and Fleet Prep Kit 3
This report displays the potential drug interactions for the following 2 drugs:
- Acid Controller Maximum Strength (famotidine)
- Fleet Prep Kit 3 (bisacodyl/sodium biphosphate/sodium phosphate)
Interactions between your drugs
No interactions were found between Acid Controller Maximum Strength and Fleet Prep Kit 3. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Acid Controller Maximum Strength
A total of 296 drugs are known to interact with Acid Controller Maximum Strength.
- Acid controller maximum strength is in the drug class H2 antagonists.
- Acid controller maximum strength is used to treat the following conditions:
Fleet Prep Kit 3
A total of 414 drugs are known to interact with Fleet Prep Kit 3.
- Fleet prep kit 3 is in the drug class laxatives.
Drug and food interactions
sodium biphosphate food
Applies to: Fleet Prep Kit 3 (bisacodyl / sodium biphosphate / sodium phosphate)
ADJUST DOSING INTERVAL: Bowel cleansing products can increase the gastrointestinal transit rate. Oral medications administered within one hour of the start of administration of the bowel cleansing solution may be flushed from the gastrointestinal tract and not properly absorbed.
MANAGEMENT: Patients should be advised that absorption of oral medications may be impaired during bowel cleansing treatment. Oral medications (e.g., anticonvulsants, oral contraceptives, antidiabetic agents, antibiotics) should not be administered during and within one hour of starting bowel cleansing treatment whenever possible. However, if concomitant use cannot be avoided, monitoring for reduced therapeutic effects may be advisable.
References
- "Product Information. Golytely (polyethylene glycol 3350 with electrolytes)." Braintree
- "Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate)." Ferring Pharmaceuticals Inc (2022):
famotidine food
Applies to: Acid Controller Maximum Strength (famotidine)
H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.
References
- Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol 38 (1990): 165-9
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.